{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T17:22:32Z","timestamp":1767374552397,"version":"3.37.3"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T00:00:00Z","timestamp":1579132800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"SPANISH AIDS Research Network","award":["(RD16\/0025\/0001, RD16\/0025\/0036 and RD16CIII\/0002\/0006)"],"award-info":[{"award-number":["(RD16\/0025\/0001, RD16\/0025\/0036 and RD16CIII\/0002\/0006)"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0226724","type":"journal-article","created":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T18:37:16Z","timestamp":1579199836000},"page":"e0226724","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immune recovery markers in a double blind clinical trial comparing dolutegravir and raltegravir based regimens as initial therapy (SPRING-2)"],"prefix":"10.1371","volume":"15","author":[{"given":"Jose-Ramon","family":"Blanco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9571-6471","authenticated-orcid":true,"given":"Belen","family":"Alejos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,1,16]]},"reference":[{"issue":"4","key":"pone.0226724.ref001","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/QAD.0000000000000545","article-title":"The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation","volume":"29","author":"NI Wada","year":"2015","journal-title":"AIDS"},{"issue":"1","key":"pone.0226724.ref002","first-page":"75","article-title":"For timing of HAART is less more? CD4+\/CD8+ ratio and CD4+ percentage as surrogate markers for more complex immunological features","volume":"37","author":"M Fogli","year":"2014","journal-title":"New Microbiol"},{"issue":"1","key":"pone.0226724.ref003","doi-asserted-by":"crossref","first-page":"e85798","DOI":"10.1371\/journal.pone.0085798","article-title":"Increased risk of serious non-AIDS-related events in HIV-infected subjects on antiretroviral therapy associated with a low CD4\/CD8 ratio","volume":"9","author":"S Serrano-Villar","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"pone.0226724.ref004","doi-asserted-by":"crossref","first-page":"e1004078","DOI":"10.1371\/journal.ppat.1004078","article-title":"HIV-infected individuals with low CD4\/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality","volume":"10","author":"S Serrano-Villar","year":"2014","journal-title":"PLoS Pathog"},{"issue":"3","key":"pone.0226724.ref005","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1016\/S2352-3018(15)00006-5","article-title":"CD4\/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study","volume":"2","author":"C Mussini","year":"2015","journal-title":"Lancet HIV"},{"issue":"7","key":"pone.0226724.ref006","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1089\/aid.2015.0385","article-title":"The CD4\/CD8 ratio is inversely associated with carotid intima-media thickness progression in human immunodeficiency virus-infected patients on antiretroviral treatment","volume":"32","author":"E Bernal Morell","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"1","key":"pone.0226724.ref007","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/hiv.12081","article-title":"The CD4:CD8 ratio is associated with markers of age-associated disease in virally suppressed HIV-infected patients with immunological recovery","volume":"15","author":"S Serrano-Villar","year":"2014","journal-title":"HIV Med"},{"issue":"4","key":"pone.0226724.ref008","doi-asserted-by":"crossref","first-page":"19480","DOI":"10.7448\/IAS.17.4.19480","article-title":"Enhanced normalisation of CD4\/CD8 ratio with early antiretroviral therapy in primary HIV infection","volume":"17","author":"J Thornhill","year":"2014","journal-title":"J Int AIDS Soc"},{"issue":"8","key":"pone.0226724.ref009","doi-asserted-by":"crossref","first-page":"e0161594","DOI":"10.1371\/journal.pone.0161594","article-title":"Low CD4\/CD8 ratio Is associated with non AIDS-defining cancers in patients on antiretroviral therapy: ANRS CO8 (Aproco\/Copilote) Prospective Cohort Study","volume":"11","author":"MN Hema","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"pone.0226724.ref010","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1086\/432955","article-title":"CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes\/mm3","volume":"192","author":"T Hulgan","year":"2005","journal-title":"J Infect Dis"},{"issue":"3","key":"pone.0226724.ref011","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/135965350901400311","article-title":"CD4+ T-cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naive patients with CD4+ T-cell counts >200 cells\/mm3","volume":"14","author":"M Guiguet","year":"2009","journal-title":"Antivir Ther"},{"issue":"2","key":"pone.0226724.ref012","first-page":"114","article-title":"CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use","volume":"2","author":"JM Taylor","year":"1989","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"pone.0226724.ref013","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/QAD.0000000000001005","article-title":"CD4+\/CD8+ ratio, age, and risk of serious noncommunicable diseases in HIV-infected adults on antiretroviral therapy","volume":"30","author":"JL Castilho","year":"2016","journal-title":"AIDS"},{"issue":"5","key":"pone.0226724.ref014","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1469-0691.2011.03650.x","article-title":"Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+\/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy","volume":"18","author":"C Torti","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"pone.0226724.ref015","article-title":"Executive summary of the GeSIDA\/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018)","author":"AIDS Study Group GeSIDA of the Spanish Society of Infectious Diseases Clinical M, the National AP","year":"2018","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"pone.0226724.ref016","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf [Accessed 30 May 2018]."},{"issue":"9936","key":"pone.0226724.ref017","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study","volume":"383","author":"B Clotet","year":"2014","journal-title":"Lancet"},{"issue":"7","key":"pone.0226724.ref018","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M14-1084","article-title":"Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial","volume":"161","author":"JL Lennox","year":"2014","journal-title":"Ann Intern Med"},{"issue":"9692","key":"pone.0226724.ref019","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0140-6736(09)60918-1","article-title":"Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial","volume":"374","author":"JL Lennox","year":"2009","journal-title":"Lancet"},{"issue":"19","key":"pone.0226724.ref020","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"SL Walmsley","year":"2013","journal-title":"N Engl J Med"},{"issue":"9868","key":"pone.0226724.ref021","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","article-title":"Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study","volume":"381","author":"F Raffi","year":"2013","journal-title":"Lancet"},{"issue":"8","key":"pone.0226724.ref022","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.cmi.2017.11.016","article-title":"Impact of dolutegravir and efavirenz on immune recovery markers: results from a randomized clinical trial","volume":"24","author":"JR Blanco","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"pone.0226724.ref023","first-page":"695","volume":"18","author":"T. A. Gooley","year":"1999","journal-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators"},{"key":"pone.0226724.ref024","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"GR Fine JP","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"11","key":"pone.0226724.ref025","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1002\/sim.2712","article-title":"Tutorial in biostatistics: competing risks and multi-state models","volume":"26","author":"H Putter","year":"2007","journal-title":"Stat Med"},{"issue":"7","key":"pone.0226724.ref026","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.3851\/IMP2350","article-title":"A pilot study to assess inflammatory biomarker changes when raltegravir is added to a virologically suppressive HAART regimen in HIV-1-infected patients with limited immunological responses","volume":"17","author":"KA Lichtenstein","year":"2012","journal-title":"Antivir Ther"},{"issue":"3","key":"pone.0226724.ref027","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jac\/dkt406","article-title":"Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study","volume":"69","author":"P Monteiro","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"pone.0226724.ref028","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/jac\/dkw375","article-title":"Different impact of raltegravir versus efavirenz on CD4\/CD8 ratio recovery in HIV-infected patients","volume":"72","author":"S Serrano-Villar","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"pone.0226724.ref029","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/cid\/cix466","article-title":"CD4:CD8 ratio and CD8 count as prognostic markers for mortality in human immunodeficiency virus-infected patients on antiretroviral therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC)","volume":"65","author":"A Trickey","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"5","key":"pone.0226724.ref030","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/0531-5565(94)90036-1","article-title":"Age-related changes in immune parameters in a very old population of Swedish people: a longitudinal study","volume":"29","author":"A Wikby","year":"1994","journal-title":"Exp Gerontol"},{"issue":"6","key":"pone.0226724.ref031","doi-asserted-by":"crossref","first-page":"B378","DOI":"10.1093\/gerona\/50A.6.B378","article-title":"Immune parameters in a longitudinal study of a very old population of Swedish people: a comparison between survivors and nonsurvivors","volume":"50","author":"FG Ferguson","year":"1995","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"2\u20133","key":"pone.0226724.ref032","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0047-6374(97)00151-6","article-title":"Changes in CD8 and CD4 lymphocyte subsets, T cell proliferation responses and non-survival in the very old: the Swedish longitudinal OCTO-immune study","volume":"102","author":"A Wikby","year":"1998","journal-title":"Mech Ageing Dev"},{"issue":"6","key":"pone.0226724.ref033","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/cid\/ciy176","article-title":"Incomplete recovery of CD4 count, CD4 percentage, and CD4\/CD8 ratio in HIV-infected patients on long-term antiretroviral therapy with suppressed viremia","volume":"67","author":"Y Mutoh","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"10","key":"pone.0226724.ref034","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/cid\/ciw076","article-title":"Determinants of a Low CD4\/CD8 Ratio in HIV-1-Infected Individuals Despite Long-term Viral Suppression","volume":"62","author":"F Caby","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"4","key":"pone.0226724.ref035","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/15284336.2016.1189754","article-title":"Characteristics associated with virologic failure in high-risk HIV-positive participants with prior failure: a post hoc analysis of ACTG 5251","volume":"17","author":"GK Robbins","year":"2016","journal-title":"HIV Clin Trials"},{"issue":"10","key":"pone.0226724.ref036","doi-asserted-by":"crossref","first-page":"e449","DOI":"10.1016\/S2352-3018(17)30110-8","article-title":"Efficacy of oral pre-exposure prophylaxis (PrEP) for HIV among women with abnormal vaginal microbiota: a post-hoc analysis of the randomised, placebo-controlled Partners PrEP Study","volume":"4","author":"R Heffron","year":"2017","journal-title":"Lancet HIV"},{"issue":"3","key":"pone.0226724.ref037","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/ACI.0b013e3283609831","article-title":"Post-hoc data analysis: benefits and limitations","volume":"13","author":"D Curran-Everett","year":"2013","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"11","key":"pone.0226724.ref038","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","article-title":"Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial","volume":"13","author":"F Raffi","year":"2013","journal-title":"Lancet Infect Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0226724","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T18:26:55Z","timestamp":1665512815000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0226724"}},"subtitle":[],"editor":[{"given":"Alan","family":"Winston","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,1,16]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0226724","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2020,1,16]]}}}